Skip to main content
Log in

Iphosphamide-induced nephrotoxicity in children

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

The nephrotoxic potential of iphosphamide was evaluated in a retrospective analysis of all children receiving the drug at The Hospital for Sick Children in Toronto. The 25 children exhibiting nephrotoxicity did not receive more cycles or higher doses per square metre than the 78 with normal renal function. Similarly, the two groups received comparable doses and number of cycles of sodium 2-mercaptoethanesulphonate, and had similar rates of exposure to nephrotoxic drugs (except forcis-platinum). Children exhibiting nephrotoxicity were significantly younger (78.1±64.1 months) than those having normal kidney function (103.8±66.6 months) (P<0.05). Children exhibiting nephrotoxicity were more likely to have receivedcis-platinum prior to the iphosphamide (10/25, 40%) than those with normal renal function (14/73, 18%) (P<0.05). Nephrotoxicity was associated with a significant effect on growth. Careful follow-up of renal function should take place in children receiving iphosphamide, with special attention paid to children younger than 5 years of age and those who have receivedcis-platinum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Jurgens H, Treuner J, Winkler K, Gobel U (1989) Iphosphamide in pediatric malignancies. Semin Oncol 16:46–50

    Google Scholar 

  2. Kushner BH, Cheung NKV (1990) Cyclophosphamide versus ifosfamide in paediatric oncology. Lancet 330:253–254

    Google Scholar 

  3. Goren MP, Wright RK, Horowitz ME, Pratt CB (1987) Ifosfamide-induced subclinical tubular nephrotoxicity despite MENSA. Cancer Treat Rep 71:127–130

    Google Scholar 

  4. Davies SM, Pearson ADJ, Craft AW (1989) Toxicity of high-dose ifosfamide in children. Cancer Chemother Pharmacol 24:S8-S10

    Google Scholar 

  5. Skinner R, Pearson ADJ, Price L, Cunningham R, Craft AW (1989) Hypophosphataemic rickets after ifosfamide treatment in children. BMJ 298:1560–1561

    Google Scholar 

  6. Moncrieff M, Foot A (1989) Fanconi syndrome after ifosfamide. Cancer Chemother Pharmacol 23:121–122

    Google Scholar 

  7. Abelson WH, Smith RG (1987) The residents handbook of pediatrics, 1th edn. The Hospital for Sick Children, Toronto, Canada.

    Google Scholar 

  8. Goodman A, and Gilman LS (1990) The pharmacological basis of therapeutics. Pergamon, New York, p 1250

    Google Scholar 

  9. Goren MP, Wright RK, Pratt CB, Horowitz ME, Dodge RK, Viar MJ, Kovnar EH (1987) Potentiation of iphosphamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by priorcis-diaminedichloroplatinum (II) therapy. Cancer Res 47:1457–1460

    Google Scholar 

  10. Skinner R, Pearson ADJ, Price L, Coulthard MG, Craft AW (1990) Nephrotoxicity after iphosphamide. Arch Dis Child 65:732–738

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shore, R., Greenberg, M., Geary, D. et al. Iphosphamide-induced nephrotoxicity in children. Pediatr Nephrol 6, 162–165 (1992). https://doi.org/10.1007/BF00866300

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00866300

Keywords

Navigation